Relevant bibliographies by topics / Prophylactic cancer vaccine

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Prophylactic cancer vaccine'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prophylactic cancer vaccine.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prophylactic cancer vaccine"

1

Khansari, Nemat. "The Future Direction of Cancer Vaccines: An Editorial." Vaccination Research – Open Journal 6, no. 1 (2022): e1-e2. http://dx.doi.org/10.17140/vroj-6-e007.

Full text
Abstract:
In the past, vaccines were defined as prophylactic entities. Today, there are two types of vaccines: prophylactic for prevention, and therapeutic for the treatment of infections or cancers. Therapeutic cancer vaccine, in fact, represents an option for active immunotherapy for the treatment of late-stage and/or prevention of recurrent diseases.1
APA, Harvard, Vancouver, ISO, and other styles
2

Bősze, Péter. "The first vaccine against cancer: the human papillomavirus vaccine." Orvosi Hetilap 154, no. 16 (2013): 603–18. http://dx.doi.org/10.1556/oh.2013.29593.

Full text
Abstract:
The last 20 years is one of the most remarkable periods in the fight against cancer, with the realization that some human papillomaviruses are causally related to cancer and with the development of the vaccine against human papillomavirus infections. This is a historical event in medicine and the prophylactic human papillomavirus vaccines have provided powerful tools for primary prevention of cervical cancer and other human papillomavirus-associated diseases. This is very important as human papillomavirus infection is probably the most common sexually transmitted infection worldwide, and over
APA, Harvard, Vancouver, ISO, and other styles
3

Toft, Lars, Martin Tolstrup, Merete Storgaard, Lars Østergaard, and Ole S. Søgaard. "Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives." Sexual Health 11, no. 6 (2014): 511. http://dx.doi.org/10.1071/sh14015.

Full text
Abstract:
Background Men and women with HIV infection are at increased risk of developing cancers associated with human papillomavirus (HPV). The two licensed prophylactic HPV vaccines protect against de novo infection with HPV-16 and HPV-18, which cause the majority of HPV-associated cancers. Currently, no vaccine efficacy data are available for persons with HIV infection. Nevertheless, some countries have implemented specific HPV vaccination recommendations for HIV-positive populations. To specifically recommend prophylactic HPV vaccination in people with HIV, the vaccines must be safe and immunogenic
APA, Harvard, Vancouver, ISO, and other styles
4

Lowy, Douglas R., and John T. Schiller. "Papillomaviruses: prophylactic vaccine prospects." Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1423, no. 1 (1999): M1—M8. http://dx.doi.org/10.1016/s0304-419x(98)00037-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dillner, Joakim, and Darron R. Brown. "Can genital-tract human papillomavirus infection and cervical cancer be prevented with a vaccine?" Expert Reviews in Molecular Medicine 6, no. 9 (2004): 1–21. http://dx.doi.org/10.1017/s1462399404007653.

Full text
Abstract:
Human papillomavirus (HPV) infection is the cause of squamous cell carcinoma of the uterine cervix. This causative relationship has provided the rationale and incentive for development of a prophylactic vaccine. Such a vaccine, if found to be effective, could reduce the need for cervical cancer screening and have a profound effect on the incidence of cervical and other anogenital cancers. This review begins by examining the basic biological and epidemiological principles relevant to the development of HPV preventative vaccines. It then summarises studies examining the use of vaccines to preven
APA, Harvard, Vancouver, ISO, and other styles
6

Poole, I. Caroline Le, Hemamalini Bommiasamy, Maurizio Bocchetta, and W. Martin Kast. "Advances in prophylactic cancer vaccine research." Expert Review of Anticancer Therapy 3, no. 4 (2003): 537–45. http://dx.doi.org/10.1586/14737140.3.4.537.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sehnal, Borek, Daniel Driák, Monika Nipčová Džubáková, and Jiří Sláma. "Current data on the efficacy of prophylactic HPV vaccination in the primary prevention of cervical lesions." Česká gynekologie 87, no. 2 (2022): 124–30. http://dx.doi.org/10.48095/cccg2022124.

Full text
Abstract:
Objective: A review of current knowledge on the efficacy of HPV (human papillomavirus) HPV vaccination against pre-cancers and cervical cancer. Methods and results: HPV infection is probably the most common sexually transmitted disease and the cause of approximately 5% of all human cancers. Currently, three prophylactic vaccines against HPV infection are on the market: bivalent Cervarix, quadrivalent Gardasil (formerly Silgard) and nonavalent Gardasil9. The Czech Republic is one of the countries with a national vaccination program where HPV vaccination is covered by health insurance for girls
APA, Harvard, Vancouver, ISO, and other styles
8

Bencherif, Sidi, Dobrin Draganov, Sarah Lewin, et al. "Immunologically active cryogels for breast cancer therapy (P4329)." Journal of Immunology 190, no. 1_Supplement (2013): 126.1. http://dx.doi.org/10.4049/jimmunol.190.supp.126.1.

Full text
Abstract:
Abstract Passive immunotherapy has become an effective adjunct for the treatment of HER2/neu-overexpressing breast cancers, as patients can respond well to monoclonal antibodies such as trastuzumab (anti-HER-2/neu antibody therapy). However, patients with late-stage disease, who often become immunosuppressed are unlikely to respond, motivating the development of new prophylactic vaccines. To this end, we have developed an injectable, polymer-based cryogel vaccine containing living, attenuated HER-2/neu-overexpressing breast cancer cells. The cryogel-based vaccine mimics key aspects of bacteria
APA, Harvard, Vancouver, ISO, and other styles
9

CASTLE, P. E., and M. MAZA. "Prophylactic HPV vaccination: past, present, and future." Epidemiology and Infection 144, no. 3 (2015): 449–68. http://dx.doi.org/10.1017/s0950268815002198.

Full text
Abstract:
SUMMARYHuman papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11
APA, Harvard, Vancouver, ISO, and other styles
10

Riolobos, Laura, Ekram Gad, Piper M. Treuting, Andrew Timms, and Mary Lenora Disis. "Development of a prophylactic vaccine for lung squamous cell carcinoma." Journal of Immunology 204, no. 1_Supplement (2020): 169.9. http://dx.doi.org/10.4049/jimmunol.204.supp.169.9.

Full text
Abstract:
Abstract High-grade bronchial dysplasia is a marker for high risk of lung squamous cell carcinoma (SCC). Cancer vaccines targeting dysplasia could prevent the progression to SCC and decrease lung cancer incidence in population at risk. In order to develop a vaccine to prevent lung SCC we need to identify antigens and epitopes within them able to elicit a potent Type I anti-tumor immune response. One caveat to develop a prophylactic vaccine targeting dysplasia is that driver mutations (neo-antigens) are not known. Many mutations appear late in lung cancer and are not shared between patients. Ho
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prophylactic cancer vaccine"

1

Carpanese, Debora. "A natural polymer (NPX) as a new adjuvant for breast cancer vaccination strategies." Doctoral thesis, Università degli studi di Padova, 2015. http://hdl.handle.net/11577/3423914.

Full text
Abstract:
The use of proteins or peptides as immunogens is attractive for the development of vaccines, especially cancer vaccines, but requires efficient and safe adjuvant formulations to overcome their intrinsic weak immunogenicity. Although dozens of different adjuvants have been shown to be effective in preclinical and clinical studies, alum remains the only one approved for human use in the USA and the most employed worldwide, but it turned out to be inefficient in cancer vaccine formulations. Indeed, the prerequisites for an ideal cancer adjuvant differ from conventional adjuvants. Since cancer vac
APA, Harvard, Vancouver, ISO, and other styles
2

"Investigation of Tumor Frame Shift Antigens for Prophylactic Cancer Vaccine, Cancer Detection and Tumorigenicity." Doctoral diss., 2012. http://hdl.handle.net/2286/R.I.15925.

Full text
Abstract:
abstract: Cancer is one of the most serious global diseases. We have focused on cancer immunoprevention. My thesis projects include developing a prophylactic primary and metastatic cancer vaccines, early cancer detection and investigation of genes involved in tumor development. These studies were focused on frame-shift (FS) antigens. The FS antigens are generated by genomic mutations or abnormal RNA processing, which cause a portion of a normal protein to be translated out of frame. The concept of the prophylactic cancer vaccine is to develop a general cancer vaccine that could prevent healthy
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Prophylactic cancer vaccine"

1

Burchell, Ann, and Eduardo Franco1. The impact of immunization on cancer control: the example of HPV vaccination. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199550173.003.0006.

Full text
Abstract:
Chapter 6 reviews briefly the role of infections as causal agents in cancer, describes anti-hepatitis B virus (HBV) immunization as the first cancer vaccine paradigm, and finally focuses on the latest paradigm of prophylactic vaccination against human papillomavirus (HPV) infection as the new front in cancer prevention.
APA, Harvard, Vancouver, ISO, and other styles
2

Prophylactic HPV Vaccines for Cervical Cancer. Oxford University Press, Incorporated, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Prophylactic cancer vaccine"

1

Pushko, Peter, and Irina Tretyakova. "Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention." In Novel Technologies for Vaccine Development. Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1818-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Beatty, Pamela L., and Olivera J. Finn. "Prophylactic Cancer Vaccines." In The Tumor Immunoenvironment. Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6217-6_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Monsonego, Joseph. "Prevention of Cervical Cancer: Challenges and Perspectives of HPV Prophylactic Vaccines." In Emerging Issues on HPV Infections. KARGER, 2006. http://dx.doi.org/10.1159/000092755.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Prophylactic Vaccine." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_6473.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

"Prophylactic Vaccine Therapy." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4773.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Mills, Jacqueline M., and Elizabeth A. Stier. "Human Papillomavirus Infection of the Cervix." In 50 Studies Every Obstetrician-Gynecologist Should Know. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780190947088.003.0031.

Full text
Abstract:
In 1992 Lorincz et al. were the first to evaluate the clinicopathologic correlation with 11 recently identified human papillomavirus (HPV) genotypes: 31, 33, 35, 42, 43, 44, 45, 51, 52, 56, and 58. Using cervical samples from 8 studies that included specimens from 2627 women, HPV genotypes were categorized by the likelihood of association with grades of cervical neoplasia (from normal to cancer). These findings were the basis of the determination that (a) HPV causes cervical cancer, (b) detection of the cancer associated HPV genotypes could identify women at risk for cervical pre-cancer and cancer, and (c) a prophylactic HPV vaccine should include protection against (at least) HPV 16 and 18.
APA, Harvard, Vancouver, ISO, and other styles
7

Beatty, Pamela L., and Olivera J. Finn. "Therapeutic and Prophylactic Cancer Vaccines." In Encyclopedia of Immunobiology. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-12-374279-7.17020-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roden, Richard BS. "Chapter 12 Second-generation HPV prophylactic vaccines." In Vaccines for the Prevention of Cervical Cancer. Oxford University Press, 2008. http://dx.doi.org/10.1093/med/9780199543458.003.0012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kitchener, Henry C. "Chapter 8 Prophylactic HPV vaccination: current status." In Vaccines for the Prevention of Cervical Cancer. Oxford University Press, 2008. http://dx.doi.org/10.1093/med/9780199543458.003.0008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Brabin, Loretta. "Chapter 9 Introduction of HPV prophylactic vaccination." In Vaccines for the Prevention of Cervical Cancer. Oxford University Press, 2008. http://dx.doi.org/10.1093/med/9780199543458.003.0009.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prophylactic cancer vaccine"

1

Luhui, Shen, Hojoon Lee, Kathryn Sykes, and Stephen Albert Johnston. "Abstract 469: Progress towards developing a universal, prophylactic cancer vaccine." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-469.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Miller, Michelle L., Jason Lohmueller, John R. McKolanis, Robert Schoen та Olivera J. Finn. "Abstract 5643: TCRβ repertoire analysis from a prophylactic MUC1 cancer vaccine trial". У Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5643.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lohmueller, Jason J., Shuji Sato, Wan Cheung Cheung, et al. "Abstract 2509: Human anti-MUC1 antibodies elicited by a prophylactic cancer vaccine for mAb and CAR-modified T cell immunotherapies." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2509.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Luhui, Shen, Kathryn Sykes, and Stephen Albert Johnston. "Abstract 1570: Frameshift peptides as prophylactic cancer vaccines antigens." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1570.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jagu, Subhashini, Balasubramanyam Karanam, Ratish Gambhira, et al. "Abstract B93: Concatenated multitype L2 fusion proteins as prophylactic human papillomavirus vaccines." In Abstracts: Frontiers in Cancer Prevention Research 2008. American Association for Cancer Research, 2008. http://dx.doi.org/10.1158/1940-6207.prev-08-b93.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prophylactic cancer vaccine' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography